A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Celcuity Inc. CELC
Weak broader-coverage candidate · Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of
On FrontierLab's discovery record since 2026-07-23 (4 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-24), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | 0 |
| Rule of 40 | — |
| Net margin | — |
| Cash runway (months) | 10.1 |
| PEG | — |
| Price / sales | — |
Quality checklist
- ✗ Gross profits / assets — 0 (pass ≥ 0.33)
- ✗ Cash generation
- ✗ Share dilution — 26.5%
Fundamentals — snapshot as of 2026-07-24
| Stage | Established |
|---|---|
| Share issuance (YoY) | 26.5% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-3.89 |
| Burn multiple | — |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.35 |
| Net debt / EBITDA | — |
| Statements as of | Q1 FY2026 · filed 2026-05-14 |
Momentum context — a snapshot from 2026-07-24, not current
| Price at surface | $88.34 (as of 2026-07-24) |
|---|---|
| 52-week range | $13.59 – $151.02 |
| % off 52-wk high | -41.5% |
| RSI (14) | 40 |
| Relative volume | 1× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-07-24 (end-of-day). How grades are computed →